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Background. The Centers for Disease Control and Prevention (CDC) uses standardized antimicrobial administration ratios
(SAARs)—that is, observed-to-predicted ratios—to compare antibiotic use across facilities. CDC models adjust for facility characteristics when predicting antibiotic use but do not include patient diagnoses and comorbidities that may also affect utilization.
This study aimed to identify comorbidities causally related to appropriate antibiotic use and to compare models that include these
comorbidities and other patient-level claims variables to a facility model for risk-adjusting inpatient antibiotic utilization.
Methods. The study included adults discharged from Premier Database hospitals in 2016–2017. For each admission, we extracted facility, claims, and antibiotic data. We evaluated 7 models to predict an admission’s antibiotic days of therapy (DOTs): a CDC
facility model, models that added patient clinical constructs in varying layers of complexity, and an external validation of a published
patient-variable model. We calculated hospital-specific SAARs to quantify effects on hospital rankings. Separately, we used Delphi
Consensus methodology to identify Elixhauser comorbidities associated with appropriate antibiotic use.
Results. The study included 11 701 326 admissions across 576 hospitals. Compared to a CDC-facility model, a model that added
Delphi-selected comorbidities and a bacterial infection indicator was more accurate for all antibiotic outcomes. For total antibiotic
use, it was 24% more accurate (respective mean absolute errors: 3.11 vs 2.35 DOTs), resulting in 31–33% more hospitals moving into
bottom or top usage quartiles postadjustment.
Conclusions. Adding electronically available patient claims data to facility models consistently improved antibiotic utilization
predictions and yielded substantial movement in hospitals’ utilization rankings.
Keywords. antibiotic stewardship; antimicrobial use; benchmarking; risk adjustment.
Reducing inappropriate antibiotic use in inpatient settings is
a nationally recognized priority for combating antibiotic resistance [1]. A system for measuring and comparing antibiotic use across hospitals is fundamental to achieving this goal:
comparator data help facilities contextualize their use against
other institutions and, by identifying outlier hospitals, may
uncover targets for intervention to improve antibiotic utilization. However, because hospitals treat different types of patients
with different diagnoses and underlying conditions, usage rates

Received 3 May 2020; editorial decision 17 July 2020; published online 5 August 2020.
Correspondence: K. E. Goodman, University of Maryland School of Medicine Baltimore, MD
(kgoodman@som.umaryland.edu).
Clinical Infectious Diseases®  2021;73(11):e4484–92
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases
Society of America. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any
medium, provided the original work is not altered or transformed in any way, and that the
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/cid/ciaa1127

e4484 • cid 2021:73 (1 December) • Goodman et al

across hospitals may appropriately vary [2]. Although it is impossible to control for every variable that affects rates of antibiotic use, controlling (“risk-adjusting”) for the most important
factors facilitates fairer and more meaningful interhospital
comparisons.
Facilities that submit antibiotic utilization data to the Centers
for Disease Control and Prevention (CDC) National Healthcare
Safety Network (NHSN) Antimicrobial Use and Resistance
Module can receive standardized antimicrobial administration
ratios (SAARs) for select units [3]. SAARs compare a hospital
unit’s observed-to-predicted antibiotic utilization (also historically called “observed-to-expected” ratios [4]). Currently, CDC
statistical models adjust for unit type and certain hospital characteristics to calculate predicted antibiotic use [5, 6]. As CDC
has itself recognized, however, additional patient factors may
also affect antibiotic utilization [6, 7]. For example, some of the
potentially relevant clinical constructs that NHSN models do
not directly adjust for when predicting antibiotic use include
patient diagnoses and comorbidities. To this end, a recent study

by Yu et al (2018) explored a large number of patient-level variables for comparing unit-level antibiotic use across 35 Kaiser
Permanente California hospitals and found that many were significantly associated with antibiotic use in their risk-adjustment
models [4].
Although SAARs are not currently used for public reporting
or reimbursement purposes, they are National Quality Forum
(NQF)-endorsed and are currently a quality and efficiency
Measure under Consideration by the Centers for Medicare and
Medicaid Services (CMS) [6, 8]. Yu et al’s findings, coupled with
other prior research [9], provide mounting evidence that any
candidate SAAR model should account for patient-mix to optimize antibiotic utilization comparisons. However, translating
this conclusion into models suitable for wider policy use also
raises additional considerations. Models would need to be validated beyond a single hospital network or geographic region
and preferably across an entire facility, including the many
unit locations that do not currently qualify for NHSN SAARs.
Ideally, too, models would only include readily implementable
patient variables, that is, those that are easily electronically
available, relatively standardized across facilities, and available
for all discharges. And most importantly, to mitigate against the
risk of unfairly penalizing hospitals, to the fullest extent possible models would predict appropriate antibiotic use [10].
Motivated by the preceding considerations, the objective
of the current study was to compare models that incorporate
claims data-derived patient variables to the current CDC NHSN
facility-variable model for risk-adjusting inpatient antibiotic
utilization. To achieve this goal, we (1) convened an expert
panel to identify patient comorbidities, derived from electronically available claims data, that are perceived as causally related
to appropriate antibiotic use; (2) evaluated, across a large and
diverse cohort of US hospitals, whether models that incorporate
these comorbidities and other patient diagnoses are more accurate than models that only include facility-level variables; and
(3) quantified the impact of adjustment with patient-variable
models on hospital antibiotic utilization rankings.
METHODS
Study Population and Collected Data

A description of the study cohort has been published previously [11]. Briefly, adult admissions and associated data were
collected from hospitals in the Premier Healthcare Database
(“Premier Database”), an all-payer repository of claims and
clinical data from more than 870 million inpatient and outpatient US hospital admissions [12]. Although not explicitly
nationally representative, Premier Database hospitals cover
highly geographically diverse areas across the United States
(see Supplementary Materials for further database detail). All
admissions with discharge dates on or between 1 January 2016
and 31 December 2017 at hospitals that continuously submitted

data during the study were included. This study did not include
personally identifiable information and was exempt from institutional review board review.
For each admission, we extracted (a) facility characteristics;
(b) payer and sociodemographic data; (c) location by serviceday; (d) daily antibiotic charge data; (e) the Medicare SeverityDiagnosis Related Group (MS-DRG) code, which guides CMS
reimbursement; and (f) all ICD-10-CM diagnosis codes, including whether diagnoses were present on admission (POA).
Using publicly available Agency for Healthcare Research and
Quality (AHRQ) software, we mapped ICD-10-CM diagnosis
codes to 3 clinical constructs: (1) 29 Elixhauser comorbidities
[13]; (2) approximately 287 Clinical Classifications Software
(CCS) disease categories [14]; and (3) 2 “bacterial infection” indicators based upon (a) any or (b) POA-only bacterial infectionrelated ICD-10-CM codes [15] (see Supplementary Figure 1).
Antibiotic Utilization Outcomes

We selected study outcomes to match current CDC NHSN antimicrobial use surveillance practice. We used inpatient days of
therapy (DOT) as the primary study metric [3, 9, 16, 17]. If a
patient received 2 different antibiotics on the same service day,
these events qualified as 2 DOTs [2, 11, 12]. For each admission,
we summed a patient’s DOTs for 4 antibiotic outcomes, mapped
to existing CDC groupings: (1) all antibiotics, (2) broad-spectrum antibiotics predominantly used for hospital-onset infections, (3) broad-spectrum antibiotics predominantly used for
community-acquired infections, and (4) antibiotics predominantly used for resistant gram-positive infections (antibiotic
appendix available in reference [3]).
Expert Panel Evaluation of Elixhauser Comorbidities Associated With
Appropriate Antibiotic Use

We used Delphi methodology [18, 19], a consensus-building
technique that has been applied to other infectious disease
outcomes [20], to determine which Elixhauser comorbid conditions are causally associated with appropriate antibiotic use
as judged by an expert panel. In this context, “associated with
appropriate antibiotic use” could mean that the comorbidity includes condition(s) for which antibiotic initiation is generally
justified (eg, patients with metastatic cancer are likely to be receiving chemotherapy, and earlier and broader-spectrum antibiotic therapy for suspected infection may be appropriate), or
that presence of the comorbidity is on average associated with
appropriately greater days of antibiotic therapy compared to an
equivalent patient without the comorbidity.
We administered an iterative, 2-round survey with conference call to 8 infectious disease and antimicrobial stewardship experts in the United States (see Supplementary Table 1).
Experts were instructed to independently rate each Elixhauser
comorbid condition on a Likert scale from 1 (not at all related)
to 5 (strongly related), based on its perceived relatedness to
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Figure 1. Results for the 7 evaluated models on the testing set (n = 5 850 663 admissions), with (A) model accuracy captured by MAEs. MAEs reflect the average days of
antibiotic therapy mis-predicted per admission. Calibration plots in (B) and (C) reflect the concordance between observed and predicted DOTs by decile for the CDC ParallelFacility model and the Expert Panel Consensus-Driven + Bacterial Infection model, respectively, for predicting total antibiotic use. Abbreviations: CDC, Centers for Disease
Control and Prevention; DOT, day of therapy; MAE, mean absolute error.

appropriate antibiotic use. At the conclusion of the Delphi process, each comorbidity was assigned as “causally related,” “indeterminately related,” or “not causally related” to appropriate
antibiotic use; criteria for determining causal relatedness have
been described in detail elsewhere [21], and we deployed the
same criteria here. Elixhauser comorbid conditions that qualified as causally related or indeterminately related to appropriate
antibiotic use were included as predictors in our Expert Panel
Consensus-Driven model.

relationships with antibiotic use. In addition, we recreated and
externally validated, as closely as our data permitted, a previously published model by Yu et al, the “Simplified ASP” model
[4]. Following our primary analyses, we also evaluated a combination model that combined the Yu et al model with our bestperforming model. Supplementary Table 2 provides variable
operationalization details for all evaluated models.

Evaluated Models

Descriptive statistics for patient and hospital characteristics
were calculated using mean (standard deviation [SD]), median (range or interquartile range [IQR]), or frequency count
(percentage). For model evaluation, we randomly divided the
dataset into 50/50 training and testing sets. All models used
negative binomial regression to predict the DOTs for an admission, for each of the 4 antibiotic outcomes; the model offset
equaled the natural log of the admission’s service-days.
For each model, we (1) fit the model on the training set and
stored model parameters; (2) applied the parameterized model
to the held-out testing set to predict each admission’s DOTs; (3)
calculated the absolute error for each admission by comparing
predicted to observed DOTs; and (4) for the entire testing set,

For each outcome, we selected 7 models a priori to predict a
patient’s antibiotic DOTs during an admission (Table 1). Our
guiding objective was to build sequentially on a base model to
evaluate the incremental performance gains, if any, achieved
by adding additional variables. This process progressed from a
model with no predictors to a model with only facility characteristics (approximating the existing CDC NHSN model),
and then to models that added the Expert Panel-selected
Elixhauser comorbid conditions and other claims data-derived
patient variables that represented different clinical constructs.
All models and their included variables, apart from a datadriven model, were selected a priori based upon hypothesized
e4486 • cid 2021:73 (1 December) • Goodman et al

Statistical Methods, SAAR Calculations, and Evaluating Impact on
Hospital Rankings

Table 1.

Description of Evaluated Models

Number Model Name
1

Null

Predictors

2

CDC ParallelFacility

3

Expert Panel •[All model #2 variables]
Consensus- •Patient age
Driven
•Elixhauser comorbidities
ranked as causally or indeterminately related to appropriate antibiotic use by the
Delphi-consensus process
•Total Elixhauser score

4

Expert Panel •[All model #3 variables]
Consensus- •Patient has an ICD-10-CM
Driven +
code associated with bacteBacterial
rial infection
Infection

5

POA Variant:
Expert
Panel ConsensusDriven +
Bacterial
Infection

6

7

Notes

None (offset only)
•Facility characteristics
•% of patient’s encounter
days in ICUs
•% of patient’s encounter
days in wards
•% of patient’s encounter
days in stepdown units
•% of patient’s encounter
days in hematologyoncology units

Variables were
selected to parallel existing CDC
NHSN SAAR
risk-adjustment
models. Supplementary Table 2
reflects the full
list of facility
characteristics.

•[All model #2 variables]
Because hospital•Elixhauser comorbidities
onset infections
ranked as causally or inare not POA, for
determinately related to
the broad-specappropriate antibiotic use
trum antibiotics
by the Delphi-consensus
predominantly
process that were coded as
used for hospitalpresent on admission
onset infections
•Total Elixhauser score (POA
category, the
conditions only)
model did not
•Patient has an ICD-10-CM
restrict bacterial
code associated with bacteinfections to POA
rial infection that was coded
as present on admission

Consensus•[All model #4 variables]
Driven/Data- •Clinical Classifications
Driven HySoftware (CCS) disease
brid
category variables retained
in crossvalidated lasso regression

Full details of the
variable selection
process are
available in the
Supplementary
Materials

Yu et al. “ASP
Simplified”
Model

Additional details
are provided in
Supplementary
Table 2

•Available in: Yu et al (2018)

methodology but adapted to predict at the hospital, rather than
unit, level (see Equation 1 in the Supplementary Materials). A
SAAR >1 indicates the hospital reported higher antibiotic use
than predicted, whereas a SAAR <1 indicates lower use than
predicted.
We used model-specific SAARs to quantify effects of adjustment on hospital rankings of antibiotic use. Given the large
number of evaluated hospitals, we used quartile rankings.
We ranked hospitals by quartile based upon their unadjusted
(observed) rates of antibiotic DOTs per 1000 patient-days.
We then reranked hospitals by their SAARs, and unadjusted
and SAAR rankings were compared. To assess the practical
impact of adding patient-level variables to risk-adjustment
models, we evaluated the number of hospitals that changed
in the bottom and top quartiles of use when adjusting with
models that included patient-level variables versus when
adjusting with a model that only included facility-level variables. Analyses were performed using SAS version 9.4 (SAS
Institute Inc.).
RESULTS

During the 24-month study period, there were 11 701 326 admissions (64 064 632 patient-days) across 576 US hospitals.
Hospital and patient characteristics are presented in Table 2.
Overall, 65% of patients received at least 1 antibiotic during
their hospitalization. Across all admissions, the DOT distribution for each antibiotic outcome was the following [(mean),
25th, 50th, 75th, 95th percentiles]: all antibiotics: (3.91), 0, 2,
5, 15; antibiotics for hospital-onset infections: (0.89), 0, 0, 0, 6;
Table 2. Description of Patient and Facility Characteristics Among US
Adult Inpatient Admissions in the Premier Healthcare Database, 2016–2017
Encounters

n = 11 701 326

No. of admissions by year

Abbreviations: CDC, Centers for Disease Control and Prevention; ICU, intensive care unit;
NHSN, National Healthcare Safety Network; POA, present on admission; SAAR, standardized antimicrobial administration ratio.

2016

5 834 810

2017

5 866 516

Total patient-days

64 064 632

Patient characteristics

n = 11 701 326 (%)

Age, median (IQR)
Male

calculated the mean absolute error (MAE) by averaging all admission errors. We used the MAE from the testing set to evaluate model accuracy [22] and compared models using raw
MAEs and percentage reductions in MAEs between candidate
Ä MAE −MAE
ä
Ref
Candidate
and reference models [
× 100]. We evaluated
MAERef
model calibration by dividing predicted DOTs into deciles. For
each decile, we calculated the mean observed and predicted
DOTs and created calibration plots for visual inspection.
We calculated each hospital’s SAARs by summing its admissions’ observed and predicted DOTs, similar to current NHSN

62 (42–75)
4 834 283 (41)

Race
  White

8 690 211 (75)

  Black

1 651 263 (14)

  Other

1 135 218 (10)

  Unknown

224 634 (2)

Payer
  Medicare

5 829 127 (50)

  Medicaid

1 976 689 (17)

  Private

3 065 584 (26)

  Other

829 926 (7)

Length of stay in days, median (IQR)
Died

4 (3–6)
258 668 (2)
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Table 2.

Continued

Encounters

n = 11 701 326

Top 5 MS-DRGsa
Vaginal delivery w/o complicating diagnosis

828 478 (7)

Septicemia or severe sepsis w/o MV >96 hours
w/ MCC

509 476 (4)

Major joint replacement or reattachment of
lower extremity w/o MCC

483 684 (4)

Cesarean section w/o CC/MCC

284 173 (2)

Heart failure and shock w/ MCC

258 083 (2)

Top 5 Elixhauser comorbiditiesa,b
Hypertension

4 830 425 (41)

Fluid and electrolyte disorders

3 500 288 (30)

Chronic pulmonary disease

2 783 243 (24)

Deficiency anemias

2 330 685 (20)

Congestive heart failure

2 055 661 (18)
c

Elixhauser comorbidity score, median (IQR)

3 (1–5)

a,c

Top 5 CCS disease categories
Essential hypertension

4 334 551 (37)

Disorders of lipid metabolism

4 191 814 (26)

Fluid and electrolyte disorders

3 499 631 (30)

Other nutritional- endocrine- and metabolic
disorders

3 277 471 (28)

Coronary atherosclerosis and other heart disease

2 796 670 (24)

Facility characteristics

n = 576 (%)

Urband

432 (75)

Teaching

170 (30)

Bed size
  0–99

126 (22)

  100–199

143 (25)

  200–299

102 (18)

  300–399

82 (14)

  400–499

41 (7)

  500+

82 (14)

antibiotics for community-acquired infections: (0.96), 0, 0, 1, 5;
and antibiotics for resistant gram-positive infections: (0.63), 0,
0, 0, 4. In other words, taking total antibiotic use as an example,
50% of all admissions had ≤2 days of therapy, and 95% of admissions had ≤15 DOTs.
Of the 29 Elixhauser comorbidities, 14 were ranked as causally related to appropriate antibiotic use at the conclusion of
the Delphi-consensus process, and a further 6 were ranked as
indeterminately related (Table 3). In total, these 20 variables,
plus patient age and total Elixhauser comorbidity score, were
included in our Expert Panel Consensus-Driven model.
Model Performance for Predicting Antibiotic Utilization (DOTs)

Models’ mean absolute errors (average days of antibiotic
therapy mispredicted per admission), and calibration plots
for select models, are reflected in Figure 1. Overall, models
were most accurate at predicting use of antibiotics for resistant
gram-positive infections and least accurate at predicting total
antibiotic use.
Building upon a null model with no variables (“Null” model),
we added facility-level variables that were selected to match
current CDC NHSN models as closely as possible (our “CDC
Parallel-Facility” model). The CDC Parallel-Facility model improved predictions over the Null model by 1.3–2.4%. Adding
Expert Panel-selected Elixhauser comorbidities, patient age,

Table 3. Relationship Between Elixhauser Comorbidities and Appropriate
Antibiotic Use, as Rated by an Expert Panela Using Delphi Consensus
Methodology

US Census Region and Division
Northeast
Mid-Atlantic
New England
South
East South Central
West South Central
South Atlantic
Midwest

63 (11)

Causally Related, n = 14

Indeterminately Related,
n=6

Not Causally
Related, n = 9

13 (2)

Valvular disease

Congestive heart failure

Hypertension

Peripheral vascular disease

Pulmonary circulation
disorders

Hypothyroidism

Paralysis

Other neurological
disorders

Coagulation
deficiencies

Chronic pulmonary disease

Diabetes without chronic
complications

Solid tumor without
metastasis

Diabetes with chronic
complications

Metastatic cancer

Fluid and electrolyte disorders

Renal failure

Weight loss

Blood loss anemia

76 (13)

260 (45)
37 (6)
62 (11)
161 (28)
147 (26)

West North Central

46 (8)

East North Central

101 (18)

West

93 (16)

Mountain

25 (4)

Pacific

68 (12)

Liver disease

Deficiency
anemias

Abbreviations: CC, complication or comorbidity; CCS, Clinical Classifications Software
(maintained by the Agency for Healthcare Research and Quality [AHRQ]); IQR, interquartile
range; MCC, major complication or comorbidity; MS-DRG, Medicare Severity-Diagnosis
Related Group; MV, mechanical ventilation; w/ and w/o, with and without.

Chronic peptic ulcer disease

Psychoses

HIV and AIDS

Depression

a
Each encounter receives 1, and only 1, MS-DRG assignment. Patients can have multiple
Elixhauser comorbidities and CCS diseases per encounter.

Rheumatoid arthritis/ collagen vascular diseases

b
Elixhauser comorbidity classifications modified to also include primary diagnoses.
Patient Elixhauser scores represent unweighted Elixhauser comorbidity sums (1 point per
comorbidity).

Obesity

Lymphoma

Alcohol abuse

c

Drug abuse

d
Designation provided by Premier, based upon American Hospital Association Annual
Survey response.

Abbreviation: HIV, human immunodeficiency virus.
a
Consisting of 8 infectious disease and antimicrobial stewardship experts in the United
States; details available in the Supplementary Materials.

Two most common CCS categories excluded from this listing because they do not represent disease categories: “Residual codes—unclassified” (54%) and “Other aftercare” (38%).
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and total Elixhauser score to the CDC Parallel-Facility model
(together with our “Expert Panel Consensus-Driven” model)
improved predictions over the CDC Parallel-Facility model by
a further 0.6–2.9% (Figure 1). However, adding an additional
variable for bacterial infection, as derived from ICD-10-CM
codes, achieved the most significant prediction improvements.
For predicting total antibiotic use, a model incorporating
these facility- and patient-level variables (our “Expert Panel
Consensus-Driven + Bacterial Infection” model) was 24%
more accurate than the CDC Parallel-Facility model, equating
to a reduction in average antibiotic DOTs mis-predicted per
admission from 3.107 DOTs to 2.348 DOTs. This model was
also very well calibrated for all patients except those with the
highest 90th percentile of antibiotic use (Figure 1). Our present
on admission-variant of the “Expert Panel Consensus-Driven +
Bacterial Infection” model restricted to Expert Panel-selected
Elixhauser comorbidities and bacterial infections that were
coded as present on admission, in order to reduce the risk of
adjusting for conditions that were a consequence, rather than
a cause, of antibiotic initiation. This model performed similarly to the main Expert Panel Consensus-Driven + Bacterial
Infection model (see Supplementary Figure 1 and Figure 2).
Yu et al’s “Simplified ASP” model was substantially similar
to our Expert Panel Consensus-Driven + Bacterial Infection

model for predicting total antibiotic use (<1.5-percentage point
difference) but was somewhat more accurate for the other antibiotic outcomes (6–7 percentage points). We also combined
the Yu et al model with our best-performing model, the Expert
Panel Consensus-Driven + Bacterial Infection model, which
marginally improved predictions for total antibiotic use and
antibiotics for community-acquired infections but did not improve performance for the remaining two antibiotic outcomes
(see Supplementary Table 3).
Impact of Risk-adjustment Using Patient-level Variables on Hospital
Rankings

Figure 2 describes the impact of adjustment using the CDC
Parallel-Facility model and select patient-variable models on
hospitals’ rankings of use by quartile. We ranked hospitals
from highest to lowest crude rates of antibiotic use for each
of the 4 outcomes, split these rankings into quartiles of 144
hospitals each, and then reranked hospitals by their SAARs.
The bottom or “worst” quartile corresponded to hospitals with
the highest crude usage rates or, after adjustment, the highest
SAARs; the converse applied to hospitals in the top or “best”
quartile [23, 24].
For total antibiotic use, when risk-adjusting using the
CDC Parallel-Facility model, 46 (32%) and 42 (29%) of the

Figure 2. Changes in number of hospitals ranked in the top or bottom quartiles of use, compared to rankings by unadjusted usage rates (DOTs/1000 patient-days), after riskadjustment with: the CDC Parallel-Facility model, the Expert Panel Consensus-Driven + Bacterial Infection model, and the POA) variant of the Expert Panel Consensus-Driven
+ Bacterial Infection model. Abbreviations: CDC, Centers for Disease Control and Prevention; DOT, day of therapy; POA, present on admission.
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144 hospitals in the bottom and top quartiles, respectively,
changed after adjustment (Figure 2). By comparison, when riskadjusting using the Expert Panel Consensus-Driven + Bacterial
Infection model, 61 (42%) and 55 (38%) hospitals changed in
these respective quartiles, representing 31–33% more hospital
movement compared to CDC Parallel-Facility model adjustment. Hospital movement was even more substantial under the
present-on-admission variant of our Expert Panel ConsensusDriven + Bacterial Infection model (Figure 2). Relative to adjustment with the CDC Parallel-Facility model, large quartile
movements were also observed for antibiotics for hospital-onset
infections and for resistant gram-positive infections when riskadjusting with patient-variable models (29–53% more movement into bottom or top quartiles of use when adjusting with
patient-variable models); antibiotics for community-acquired
infections yielded the smallest differences between adjustment
with the CDC Parallel-Facility model and adjustment with
patient-variable models (12–18%, Figure 2).
DISCUSSION

Across a large and diverse cohort of US hospitals, and nearly
12 million admissions, this study found that adding patientlevel data to existing, facility-variable risk-adjustment models
consistently improved predictions for inpatient antibiotic utilization. More accurate predictions produce more accurate
observed-to-predicted use ratios (eg, SAARs), the current
bedrock of antibiotic utilization comparison used by hospitals
and the CDC and the primary method for identifying outlier
prescribing. Importantly, these accuracy improvements were
achieved using variables (1) derived from patient ICD-10-CM
diagnosis codes, which are readily electronically available and
mandated for all patients discharged from HIPAA-compliant
US hospitals [25]; and (2) Elixhauser comorbidities expertrated as associated with appropriate antibiotic use. If SAARs
are eventually deployed for quality assessment or reimbursement purposes, these attributes lend practical and policy value.
Including these patient data also yielded large downstream effects on hospital rankings. For example, for ranking total antibiotic use, approximately 30% more hospitals moved into the
bottom or top quartiles after adjusting with a model that included patient variables, compared to adjusting with a model
that only included facility characteristics.
For all antibiotic outcomes, the “Expert Panel ConsensusDriven + Bacterial Infection” was our best-performing model.
The Expert Panel-selected Elixhauser comorbidities included in
this model are a distinguishing feature of this study and helped
to focus predictions more squarely on appropriate antibiotic use.
Predicting appropriate antibiotic use is a goal shared by CDC,
antibiotic stewardship programs, and other researchers [1, 10,
26]. To be clear, however, we do not intend to suggest (and
indeed, would not expect) that antibiotic use in patients with
e4490 • cid 2021:73 (1 December) • Goodman et al

these comorbid conditions is always appropriate. We further
recognize that bacterial infections, the other principal variable
in this model, may be misdiagnosed or treated with antibiotics
inappropriately. But on average across facilities, models that include these expert-selected Elixhauser conditions should yield
fairer, more accurate SAARS that protect hospitals that treat
more patients with these comorbidities from being penalized
for resultantly higher rates of antibiotic use.
The prior work that most closely relates to our current study
is a 2018 paper by Yu et al, which also compared patient-variable
models to a facility-variable model for predicting antibiotic utilization [4]. We recreated and externally validated their primary
model (“Simplified ASP”) and found that its accuracy was similar to, and in some cases a few percentage points better than,
our best-performing model. This information is new, because
although the Yu et al study established high concordance between their Simplified ASP model and a “Complex” model that
they also derived, their study did not quantify model accuracy
outright. Interestingly, both the Yu et al model and our bestperforming model were most accurate at predicting use of antibiotics for resistant gram-positive infections. We attribute this
finding not to a stronger relationship between predictors and
outcome per se but rather to low use: with 75% of admissions
having 0 DOTs for these antibiotics, even our null negative binomial model with no predictors fit the data relatively well.
Conversely, outcomes with higher DOTs, such as total antibiotics, demonstrated higher absolute errors across all tested
models but also proportionally greater error reductions as
patient-level variables were added.
More broadly, our findings and our external validation of the
Yu et al model reinforce the benefits of adding patient data to
risk-adjustment models and suggest that the accuracy improvements achieved by our and the Yu et al models are likely real
and reproducible. Of note, the Yu et al model’s most important
predictor was an admission’s MS-DRG, which is a CMS reimbursement code assigned at discharge based upon the principal
diagnosis, as well as certain secondary diagnoses and procedures [27]. Although we had MS-DRG code data available for
all admissions because Premier calculates them, we intentionally did not evaluate this variable as a predictor because some
commercial insurers do not use them, and CMS has specifically
urged caution when applying MS-DRGs to non-Medicare populations [28]. Importantly, by incorporating clinical constructs
generated exclusively from ICD-10-CM diagnosis codes, our
models should be executable regardless of payer and without
requiring additional extraction of procedure data.
Our study has several limitations. First, it did not include pediatric patients. NHSN has developed pediatric care locationspecific SAARs [6] and validating our models against existing
NHSN facility-variable models in pediatric patients would
be an important area of future study. Second, we derived
our clinical constructs from patient claims data, specifically

ICD-10-CM diagnosis codes. Although ICD-10-CM codes
have imperfect sensitivity and specificity and will not fully
capture preadmission healthcare information, from a practical perspective, claims data-based constructs are a significant
study strength, because they are available across all US hospitals and payers. However, because ICD-10-CM codes are assigned at discharge, ascertaining whether diagnoses preceded
or followed antibiotic initiation is challenging. To address this
uncertainty, we evaluated a model variant that restricted to bacterial infections and comorbidities coded as present on admission; this model performed similarly to the main model. As a
matter of policy, however, national variability in POA coding
and the potential for POA code misuse [29, 30] would require further consideration, standardization and study. Third,
we calculated antibiotic DOTs using charge data. Many large
studies have used claims data to measure antibiotic utilization
[11, 16, 17], and research has demonstrated strong agreement
between pharmacy charge and administration records for antibiotics [31], but some residual discordance between these data
sources remains possible. Fourth, we predicted antibiotic use
at the admission level because, beyond increasing study power,
it accounted for patients who move among units during their
admission. Consequently, we could closely, but not exactly, recreate unit-level prediction models (eg, CDC NHSN models,
the Yu et al model), and we therefore caution against direct
comparisons across studies.
Overall, our study found that compared to only adjusting for
facility characteristics and patient care location, adding patient
comorbidities and bacterial infection diagnoses consistently
improved models for predicting inpatient antibiotic utilization.
As such, this study in a large, diverse cohort of 576 US hospitals
adds to a growing body of evidence from prior, smaller studies:
accounting for patient-mix is necessary to optimize antibiotic
use comparisons. Importantly, our model variables were easily
derived from standard claims data and were selected to correlate more closely with appropriate antibiotic use. Moreover,
the improvements they yielded were material—a nearly 25%
reduction in the average error rate for predicting total antibiotic use and substantial movement in hospitals’ utilization
rankings. Whether, and when, SAARs are ready for reimbursement or public reporting purposes is a subjective policy question for CDC, CMS, and professional organizations; we hope
that this study provides informative evidence to guide these
deliberations. We encourage continued investigation of other,
electronically available patient data that may further improve
antibiotic utilization comparisons.
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